Pharmacyclics LLC Sustainability Profile
Pharmacyclics LLC, a subsidiary of AbbVie, is a leading biopharmaceutical company headquartered in the United States. Founded in 1991, the company has made significant strides in the oncology sector, focusing on the development of innovative therapies for blood cancers. With a strong presence in major operational regions across North America and Europe, Pharmacyclics is renowned for its flagship product, ibrutinib, a groundbreaking treatment for various types of leukaemia and lymphoma. The company has achieved notable milestones, including rapid advancements in clinical trials and regulatory approvals, solidifying its position as a key player in the oncology market. Pharmacyclics is committed to improving patient outcomes through its unique, targeted therapies, which have transformed the treatment landscape for haematological malignancies. With a focus on research and development, Pharmacyclics continues to lead the way in delivering effective solutions for patients worldwide.
DitchCarbon Score
How does Pharmacyclics LLC's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Pharmacyclics LLC's score of 65 is higher than 78% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Pharmacyclics LLC, headquartered in the US, currently does not report specific carbon emissions data, as indicated by the absence of emissions figures. The company is a current subsidiary of AbbVie Inc., which may influence its climate commitments and reporting practices. Pharmacyclics LLC's climate initiatives and reduction targets are inherited from its parent company, AbbVie Inc. This includes participation in the Science Based Targets initiative (SBTi) and the Carbon Disclosure Project (CDP), both of which are aimed at establishing and achieving significant emissions reduction targets. However, specific reduction targets or achievements for Pharmacyclics LLC are not detailed in the available data. As part of its corporate family, Pharmacyclics LLC aligns with AbbVie Inc.'s broader sustainability goals, which may include commitments to reduce Scope 1, 2, and 3 emissions. Nonetheless, without specific emissions data or defined targets, it is challenging to assess the company's individual climate impact or commitments comprehensively.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | 402,448,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | - | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 3 | - | - | - | - | - | - | - | - | - | - |
How Carbon Intensive is Pharmacyclics LLC's Industry?
How Carbon Intensive is Pharmacyclics LLC's Location?
Pharmacyclics LLC's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Pharmacyclics LLC has established climate goals through participation in recognized frameworks and target-setting initiatives. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
